Skip to content
Home
Judy L. Thompson, Ph.D.

Judy L. Thompson, Ph.D.

Contact

Call Center (585) 276-3000

Looking for more Information?

Visit my lab website to learn more about my research, collaborators, latest news, etc.

Visit Research Lab Website

About Me

Faculty Appointments

Assistant Professor - Department of Psychiatry, Research (SMD)

Assistant Professor - Department of Neuroscience (SMD) - Joint

Credentials

Post-doctoral Training & Residency

Postdoctoral Schizophrenia Research Fellowship: Department of Psychiatry, Columbia University, Postdoctoral Research Fellow 2006 - 2009

APA-Accredited Psychology Internship: Department of Psychiatry, University of Illinois-Chicago, Psychology Intern 2005 - 2006

Education

PhD | University of Pittsburgh. Clinical Psychology. 2006

Awards

Loan Repayment Program Recipient. 2008 - 2010

Honorable Mention, Smadar Levin Award. 2006

Bassell Student Publication Award. 2005

Honorable Mention, Smadar Levin Award. 2004

A. David Lazovik Research Award. 2004

Bassell Student Publication Award. 2004

Outstanding Graduate Student Award. 1997

Outstanding Graduate Student Award. 1996

Graduate Research Grants. 1995 - 1997

Phi Beta Kappa. 1992

Research

Clinical Trials

An EEG Study of Auditory Processing in People with and without Schizophrenia 

Lead Researcher: Judy Thompson

The purpose of our study is to better understand how the brain processes sounds, including speech. We are investigating this in people with and without psychiatric conditions. One of our primary aims is to determine how these processes may relate to ...

Publications

Journal Articles

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.

Addington J, Liu L, Braun A, Auther A, Calkins ME, Cornblatt BA, Corcoran CM, Fusar-Poli P, Kerr MJ, Mourgues-Codern CV, Nunez AR, Oliver D, Strauss GP, Walsh BC, Alameda LK, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Dwyer D, Ellman LM, Faghankhani M, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui C, Jacobs GR, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Penzel N, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson A, Thompson JL, Upthegrove R, Verma S, Wang J, Wastler HM, Wickham A, Rossum IW, Wolf DH, Bouix S, Pasternak O, Kahn RS, Bearden CE, Kane JM, McGorry PD, Buccilli K, Nelson B, Shenton ME, Woods SW, Yung AR

Schizophrenia.. 2025 April 311 (1):54. Epub 04/03/2025.

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.

Harms MP, Cho KK, Anticevic A, Bolo NR, Bouix S, Campbell D, Cannon TD, Cecchi G, Goncalves M, Haidar A, Hughes DE, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman JM, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack RA, Rathi Y, Romo PA, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Kahn RS, Kane JM, McGorry PD, Nelson B, Woods SW, Shenton ME, Wood SJ, Bearden CE, Pasternak O

Schizophrenia.. 2025 April 211 (1):52. Epub 04/02/2025.

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Allott K, Yassin W, Alameda L, Billah T, Borders O, Buccilli K, Carrión RE, Castillo-Passi RI, Cho KIK, Chin K, Coleman MJ, Colton BL, Corral S, Dwyer D, Gundersen KB, Gur RC, Hoftman GD, Jacobs GR, Kelly S, Lewandowski KE, Marcy PJ, Matneja P, McLaughlin D, Nunez AR, Parsa S, Penzel N, Ray S, Reinen JM, Ruparel K, Sand MS, Santorelli G, Seitz-Holland J, Spark J, Tamayo Z, Thompson A, Tod S, Wannan CMJ, Wickham A, Wood SJ, Zoupou E, Addington J, Anticevic A, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Diaz-Caneja CM, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perkins DO, Perez J, Powers AR, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Pasternak O, Bouix S, McGorry PD, Kane JM, Kahn RS, Bearden CE, Shenton ME, Woods SW, Nelson B, Stone WS

Schizophrenia.. 2025 March 2411 (1):49. Epub 03/24/2025.

Effects of visual remediation on Ebbinghaus illusion task performance in people with schizophrenia: A preliminary study.

Kaiser KA, Thompson JL, Butler PD, Ahmed AO, Seitz AR, Sobeih T, Silverstein SM

Schizophrenia research.. 2025 February 27277 :57-64. Epub 02/27/2025.

Hallucinations and the depth-inversion illusion in schizophrenia.

Thompson JL, Silverstein SM, Papathomas TV, Keane BP

Schizophrenia research.. 2024 December 274 :21-23. Epub 09/08/2024.

Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.

Bergson Z, Ahmed AO, Bell J, Butler PD, Gordon J, Seitz AR, Silverstein SM, Thompson JL, Zemon V

Schizophrenia research.. 2024 December 274 :396-405. Epub 10/30/2024.

Performance on a contour integration task as a function of contour shape in schizophrenia and controls.

Jayakumar S, Ahmed AO, Butler PD, Silverstein SM, Thompson JL, Seitz AR

Vision research.. 2024 June 219 :108394. Epub 04/04/2024.

Retinal Neurodegeneration as a Potential Biomarker of Accelerated Aging in Schizophrenia Spectrum Disorders.

Blose BA, Lai A, Crosta C, Thompson JL, Silverstein SM

Schizophrenia bulletin.. 2023 September 749 (5):1316-1324. Epub 1900 01 01.

Dorsal attention network activity during perceptual organization is distinct in schizophrenia and predictive of cognitive disorganization.

Keane BP, Krekelberg B, Mill RD, Silverstein SM, Thompson JL, Serody MR, Barch DM, Cole MW

The European journal of neuroscience.. 2023 February 57 (3):458-478. Epub 01/04/2023.

Evaluating Educational and Employment Services for Young People With Psychiatric Conditions: A Systematic Review.

Thompson JL, Holloway K, Karyczak S, Serody MR, Lane IA, Ellison ML, Gill KJ, Davis M, Mullen MG

Psychiatric services : a journal of the American Psychiatric Association.. 2022 July 73 (7):787-800. Epub 12/08/2021.

Increased face detection responses on the mooney faces test in people at clinical high risk for psychosis.

Silverstein SM, Thompson JL, Gold JM, Schiffman J, Waltz JA, Williams TF, Zinbarg RE, Mittal VA, Ellman LM, Strauss GP, Walker EF, Woods SW, Levin JA, Kafadar E, Kenney J, Smith D, Powers AR, Corlett PR

NPJ schizophrenia.. 2021 May 177 (1):26. Epub 05/17/2021.

Predicting Attention-Shaping Response in People With Schizophrenia.

Beaudette DM, Gold JM, Waltz J, Thompson JL, Cherneski L, Martin V, Monteiro B, Cruz LN, Silverstein SM

The Journal of nervous and mental disease.. 2021 March 1209 (3):203-207. Epub 1900 01 01.

Amphetamine-induced striatal dopamine release in schizotypal personality disorder.

Thompson JL, Rosell DR, Slifstein M, Xu X, Rothstein EG, Modiano YA, Kegeles LS, Koenigsberg HW, New AS, Hazlett EA, McClure MM, Perez-Rodriguez MM, Siever LJ, Abi-Dargham A

Psychopharmacology.. 2020 September 237 (9):2649-2659. Epub 06/22/2020.

Retinal functioning and reward processing in schizophrenia.

Demmin DL, Mote J, Beaudette DM, Thompson JL, Silverstein SM

Schizophrenia research.. 2020 May 219 :25-33. Epub 07/04/2019.

People with current major depression resemble healthy controls on flash Electroretinogram indices associated with impairment in people with stabilized schizophrenia.

Demmin DL, Netser R, Roché MW, Thompson JL, Silverstein SM

Schizophrenia research.. 2020 May 219 :69-76. Epub 07/30/2019.

Progress, Possibilities, and Pitfalls in Electroretinography Research in Psychiatry.

Silverstein SM, Thompson JL

Biological psychiatry.. 2020 February 187 (3):202-203. Epub 1900 01 01.

Development and Evaluation of a Visual Remediation Intervention for People with Schizophrenia.

Silverstein SM, Seitz AR, Ahmed AO, Thompson JL, Zemon V, Gara M, Butler PD

Journal of psychiatry and brain science.. 2020 5 Epub 07/20/2020.

Visual perceptual remediation for individuals with schizophrenia: Rationale, method, and three case studies.

Butler PD, Thompson JL, Seitz AR, Deveau J, Silverstein SM

Psychiatric rehabilitation journal.. 2017 March 40 (1):43-52. Epub 08/22/2016.

Evaluation of a cognitive remediation intervention for college students with psychiatric conditions.

Mullen MG, Thompson JL, Murphy AA, Malenczak D, Giacobbe G, Karyczak S, Holloway KE, Twamley EW, Silverstein SM, Gill KJ

Psychiatric rehabilitation journal.. 2017 March 40 (1):103-107. Epub 1900 01 01.

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA

Journal of psychopharmacology. 2016 May 30 (5):428-35. Epub 03/10/2016.

A vision science perspective on schizophrenia.

Silverstein SM, Thompson JL

Schizophrenia research. Cognition.. 2015 June 2 (2):39-41. Epub 1900 01 01.

Dynamic shifts in brain network activation during supracapacity working memory task performance.

Van Snellenberg JX, Slifstein M, Read C, Weber J, Thompson JL, Wager TD, Shohamy D, Abi-Dargham A, Smith EE

Human brain mapping.. 2015 April 36 (4):1245-64. Epub 11/24/2014.

Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.

Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A

JAMA psychiatry.. 2015 April 72 (4):316-24. Epub 1900 01 01.

Anhedonia in the psychosis risk syndrome: associations with social impairment and basal orbitofrontal cortical activity.

Cressman VL, Schobel SA, Steinfeld S, Ben-David S, Thompson JL, Small SA, Moore H, Corcoran CM

NPJ schizophrenia.. 2015 1 :15020. Epub 07/15/2015.

Serotonin transporter availability in impulsive aggressive personality disordered patients: a PET study with [11C]DASB.

van de Giessen E, Rosell DR, Thompson JL, Xu X, Girgis RR, Ehrlich Y, Slifstein M, Abi-Dargham A, Siever LJ

Journal of psychiatric research.. 2014 November 58 :147-54. Epub 08/06/2014.

Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ

Psychopharmacology.. 2014 October 231 (21):4231-40. Epub 04/30/2014.

Striatal dopamine release in schizophrenia comorbid with substance dependence.

Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A

Molecular psychiatry.. 2013 August 18 (8):909-15. Epub 08/07/2012.

In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia.

Poels EM, Girgis RR, Thompson JL, Slifstein M, Abi-Dargham A

Psychopharmacology.. 2013 July 228 (1):167-74. Epub 03/05/2013.

HPA-axis function, symptoms, and medication exposure in youths at clinical high risk for psychosis

Sugranyes, G.; Thompson, J. L.; & Corcoran, C. M.

Journal of Psychiatric Research. 2012; 46(11): 1389-93.

Absolute level of gamma synchrony is increased in first-episode schizophrenia during face processing

Silverstein, S. M.; All, S. D.; Thompson, J. L.; Williams, L. M.; Whitford, T. J.; Nagy, M.; Flynn, G.; Harris, A. W. F.; Galletly, C.; & Gordon, E.

Journal of Experimental Psychopathology. 2012; 4: 702-23.

Dopamine release in chronic cannabis users: a [11C]raclopride positron emission tomography study

Urban, N. B. L.; Slifstein, M.; Thompson, J. L.; Xu, X.; Girgis, R.; Raheja, S.; Haney, M.; & Abi-Dargham, A.

Biological Psychiatry. 2012; 71(8): 677-83.

Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: A PET study with [11C]NNC112

Abi-Dargham, A.; Xu, X.; Thompson, J. L.; Gil, R.; Kegeles, L. S.; Urban, N. B.; Narendran, R.; Hwang, D. R.; Laruelle, M.; & Slifstein, M.

Journal of Psychopharmacology. 2012; 26(6): 794-805.

Presynaptic dopamine in schizophrenia

Miyake, N.; Thompson, J.; Skinbjerg, M.; & Abi-Dargham, A.

CNS Neuroscience & Therapeutics. 2011; 17(2): 104-09.

The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis

Corcoran, C. M.; Kimhy, D.; Parilla-Escobar, M. A.; Cressman, V. L.; Stanford, A. D.; Thompson, J.; David, S. B.; Crumbley, A.; Schobel, S.; Moore, H.; & Malaspina, D.

Psychological Medicine. 2011; 41(2): 251-61.

Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A

Biological psychiatry.. 2010 October 168 (7):634-41. Epub 07/31/2010.

Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, Hackett E, Bae SA, Laruelle M, Abi-Dargham A

Synapse.. 2010 May 64 (5):350-62. Epub 1900 01 01.

Increased 5-HT2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients

Rosell, D. R.; Thompson, J. L.; Slifstein, M.; Xu, X.; Frankle, W. G.; New, A. S.; Goodman, M.; Weinstein, S. C.; Laruelle, M.; Abi-Dargham, A.; & Siever, L. J.

Biological Psychiatry. 2010; 67(12): 1154-62.

How have developments in molecular imaging techniques furthered schizophrenia research?

Thompson JL, Urban N, Abi-Dargham A

Imaging in medicine.. 2009 December 11 (2):135-153. Epub 1900 01 01.

Childhood trauma and prodromal symptoms among individuals at clinical high risk for psychosis.

Thompson JL, Kelly M, Kimhy D, Harkavy-Friedman JM, Khan S, Messinger JW, Schobel S, Goetz R, Malaspina D, Corcoran C

Schizophrenia research.. 2009 March 108 (1-3):176-81. Epub 01/25/2009.

Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis

Corcoran, C.; Kimhy, D.; Stanford, A.; Khan, S.; Walsh, J.; Thompson, J.; Schobel, S.; Harkavy-Friedman, J.; Goetz, R.; Colibazzi, T.; Cressman, V.; & Malaspina, D.

Schizophrenia Research. 2008; 106: 286-93.

Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance.

Thompson JL, Watson JR, Steinhauer SR, Goldstein G, Pogue-Geile MF

Schizophrenia bulletin.. 2005 January 31 (1):85-96. Epub 02/16/2005.

Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms.

Thompson JL, Pogue-Geile MF, Grace AA

Schizophrenia bulletin.. 2004 30 (4):875-900. Epub 1900 01 01.

Books

Helping Youth on the Path to Employment Manual (HYPE) (2017)